Amplification of the MLL region in acute myeloid leukemia.

Cancer Genet Cytogenet

Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.

Published: September 2000

We report amplification of the MLL gene region (11q23-->11qter) in a 72-year-old woman with myelodysplastic syndrome progressing to acute myelomonocytic leukemia and in a 51-year-old man with a history of hairy cell leukemia and secondary myelodysplasia progressing to acute myelogenous leukemia. The amplicons containing MLL were shown by molecular cytogenetics to extend from chromosomal region 11q23 to the distal long arm of chromosome 11 and to be present in the first patient in five copies on a large ring chromosome and present in the second patient also in five copies on two derived chromosomes. Other karyotypic findings in the first patient included del(5q), +8, and der(21)t(17;21), resulting in the loss of a copy of 17p, whereas deletion 7q was observed in the second patient. Southern-blot analysis for the second patient was consistent with MLL amplification but did not demonstrate rearrangement of the germ-line MLL band. Amplification of MLL and the 11q23 region has been documented in only a few cases and appears to be yet another mechanism by which MLL contributes to the leukemia phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-4608(00)00256-9DOI Listing

Publication Analysis

Top Keywords

amplification mll
12
second patient
12
progressing acute
8
patient copies
8
mll
6
leukemia
5
patient
5
amplification
4
region
4
mll region
4

Similar Publications

Toxin-antidote elements (TAs) are selfish DNA sequences that bias their transmission to the next generation. TAs typically consist of two linked genes: a toxin and an antidote. The toxin kills progeny that do not inherit the TA, while the antidote counteracts the toxin in progeny that inherit the TA.

View Article and Find Full Text PDF
Article Synopsis
  • Salivary gland carcinomas (SGC) are diverse with 24 subtypes, primarily treated through surgery and radiotherapy, but have a low 5-year survival rate of 20% for patients with recurrence or metastasis.
  • A study involving 55 SGC patients investigated various druggable molecular alterations using immunohistochemical staining and fluorescence in situ hybridization, finding a 54.4% prevalence of such alterations, with EGFR overexpression being the most common.
  • Targeted therapies like trastuzumab deruxtecan and pembrolizumab may offer new treatment options for patients with RM-SGC who cannot undergo salvage surgery.
View Article and Find Full Text PDF

Objective: To ascertain the frequency of the MLL::AF9 gene rearrangement and its association with survival in Pakistani patients suffering from acute myeloid leukaemia (AML).

Study Design: Analytical study. Place and Duration of the Study: Department of Haematology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan, from 2015 to 2020.

View Article and Find Full Text PDF

The landscape of chromosomal aberrations in the tumor cells of the patients with B-ALL is diverse and can influence the outcome of the disease. Molecular karyotyping at the onset of the disease using chromosomal microarray (CMA) is advisable to identify additional molecular factors associated with the prognosis of the disease. Molecular karyotyping data for 36 patients with Ph-negative B-ALL who received therapy according to the ALL-2016 protocol are presented.

View Article and Find Full Text PDF

Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement.

Cell

October 2023

Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111, USA; Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA. Electronic address:

MLL/KMT2A amplifications and translocations are prevalent in infant, adult, and therapy-induced leukemia. However, the molecular contributor(s) to these alterations are unclear. Here, we demonstrate that histone H3 lysine 9 mono- and di-methylation (H3K9me1/2) balance at the MLL/KMT2A locus regulates these amplifications and rearrangements.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!